Rheumatology

GCA

Questions discussed in this category

When do you consider tapering tocilizumab in patients with GCA in remission?

1 Answer available

Do you always perform temporal artery biopsy in patients with positive inflammatory markers and high clinical suspicion of GCA?

2 Answers available

Is either ESR or CRP more sensitive or specific for the diagnosis of GCA?

Additionally, what is the current role for temporal artery ultrasound in workup for GCA?

3 Answers available

How long do you continue steroid-sparing agents such as tocilizumab for GCA once the disease is in remission off steroids?

1 Answer available

At what point in GCA management do you typically introduce tocilizumab?

2 Answers available

Do you monitor RS3PE patients for GCA with the same vigilance that you do in PMR patients?

1 Answer available

Papers discussed in this category

Ann Intern Med, 2020 Sep 22

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.

N Engl J Med,

Trial of Tocilizumab in Giant-Cell Arteritis.

Lancet, 2016 Mar 04

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Seminars in arthritis and rheumatism, 2012-06

Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.

Arthritis Rheumatol, 2021 Jul 08

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.

Ann Rheum Dis, 2019 Jul 03

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Mayo Clin Proc,

My Treatment Approach to Giant Cell Arteritis.

Arthritis Care Res (Hoboken), 2020 May 19

Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.

J Rheumatol, 2021 Feb 15

Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.

Rheumatology (Oxford),

Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.

Related Topics in Rheumatology